Search

BCG strain differences have an impact on clinical outcome in bladder cancer immunotherapy

Bacillus Calmette-Guérin (BCG) has been part of the treatment algorithm for non-muscle invasive bladder cancer (NMIBC) for a number of years. In this single centre, prospective, randomised trial, two of the most commonly available strains, BCG Connaught and BCG Tice,...

Secondary bladder cancer following upper tract urothelial cancer

Upper tract urothelial carcinoma (UTUC) comprises <5% of all urothelial cancers. A certain proportion of patients with UTUC will develop secondary bladder urothelial cancer (BUC). This paper has retrospectively examined records obtained from several cancer USA population-based registries of more...

Repeat transurethral resection in non-muscle invasive bladder cancer

The authors felt this is a big problem because there is no standardised practice on re-resection following initial transurethral resection of bladder tumour (TURBT). Getting detrusor muscle in the first specimen is thought to be important. However muscle is not...

Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?

Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...

Can PET/CT help in selecting treatment for patients with muscle-invasive bladder cancer more appropriately?

Radical cystectomy is one of the most drastic procedures that urological patients have to undergo with a five-year mortality of around 50% in those with organ-confined disease at presentation. Traditional imaging is with contrast-enhanced computed tomography (CT) but lymphadenectomy often...